Current Report Filing (8-k)
January 07 2020 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2020
Zymeworks Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
British Columbia, Canada
|
|
001-38068
|
|
47-2569713
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
|
|
V6H 3V9
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(604) 678-1388
(Registrant’s telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Shares, no par value per share
|
|
ZYME
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On January 7, 2020, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that management will present a corporate overview and updated
clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. PT. On January 7,
2020, this press release was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. A copy of this press release is filed as exhibit 99.1
hereto.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ZYMEWORKS INC.
(Registrant)
|
|
|
|
|
|
|
Date: January 7, 2020
|
|
|
|
By:
|
|
/s/ Neil A. Klompas
|
|
|
|
|
|
Name:
|
|
Neil A. Klompas
|
|
|
|
|
|
Title:
|
|
Executive Vice President, Business Operations and Chief Financial Officer
|
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024
